

## **CorAssist Successfully Demonstrates CORolla™ Transapical Delivery & Positioning at the LTCS** *Live Implantation Demonstration Brings CORolla™ One Step Closer to the Clinic*

December 30, 2009, Herzliya Pituach, Israel. CorAssist Cardiovascular Ltd., a developer of novel therapeutic devices for Diastolic Heart Failure (DHF), successfully implanted the CORolla™, the first intra-ventricular device in development for DHF, in a live implantation demonstration at the LTCS (Latest Technologies in Cardiac Surgery) Congress on December 4, 2009.

The live implantation demonstration was performed on an animal model by Professor Michael Borger at the world-renown Heart Center University in Leipzig, Germany. Professor Borger successfully delivered the CORolla™ via the minimally invasive, trans-apical approach and easily positioned the device in the left ventricle. Quick and safe extraction of the device was also successfully demonstrated.

The CORolla™ is a spring-like device capable of harnessing energy during systole, and releasing energy during diastole to augment diastolic dynamics. The demonstration was well received from the audience, and generated positive feedback from cardiovascular surgeons and cardiologists, as told to CorAssist representatives in post demonstration discussions.

As a minimally invasive and therapeutic device, the CORolla™ has the potential to be a real breakthrough in DHF management. DHF is a condition in which the heart becomes stiff and/or fails to relax, and fills inadequately. Today, there are no evidence based therapeutic options for the estimated 2.5 million DHF patients in the United States.

### **About the LTCS Congress**

The LTCS Congress features new surgical techniques in the fields of heart failure, minimally invasive surgery, and transcatheter heart valve implantation, and introduces innovative surgical concepts by world expert surgeons.

More information about the LTCS Congress can be found at:  
<http://www.ltcs-leipzig.com>

### **About CorAssist Cardiovascular Ltd.**

CorAssist is a medical device company developing novel therapeutic devices for Diastolic Heart Failure (DHF). DHF is a condition in which the heart becomes stiff and/or fails to relax, and fills inadequately. Today, there are no evidence based therapeutic options for the estimated 2.5 million DHF patients in the United States.

The company's "spring-like" devices harness elastic energy produced by the left ventricle during systole (contraction) and release the energy during diastole (relaxation). The released energy assists the left ventricle to overcome its stiffness by "springing back" an appropriate amount to improve relaxation and blood filling. The company's extra-ventricular device, ImCardia™, is in a multi-center clinical trial, and has shown a positive safety profile after one year follow-up in several patients.

CorAssist was founded in 2002 by Dr. Yair Feld, Dr. Shay Dubi, and Dr. Yotam Reisner, at Naiot Incubator.

More information about the CorAssist can be found at:  
<http://www.corassist.com/>